Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 31;4(3):90.
doi: 10.3390/jof4030090.

Therapy of Mucormycosis

Nikolaos V Sipsas  1 , Maria N Gamaletsou  2 , Amalia Anastasopoulou  3 , Dimitrios P Kontoyiannis  4
Affiliations
Review

Therapy of Mucormycosis

Nikolaos V Sipsas et al. J Fungi (Basel). .

Abstract

Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.

Keywords: amphotericin B; isavuconazole; leukemia; mucormycosis; posaconazole; stem cell transplantation; surgery; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Algorithm for Mucormycosis Treatment. AMB: amphotericin B; CT: computed tomography scan; moAb: monoclonal antibodies; TDM: therapeutic drug monitoring; GM-CSF: granulocyte-macrophage colony stimulating factor; INF-γ: interferon—gamma; WBC: white blood cells.
See this image and copyright information in PMC

References

    1. Kwon-Chung K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis. 2012;54(Suppl. 1):S8–S15. doi: 10.1093/cid/cir864. - DOI - PMC - PubMed
    1. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., Sein M., Sein T., Chiou C.C., Chu J.H., et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis. 2005;41:634–653. doi: 10.1086/432579. - DOI - PubMed
    1. Gomes M.Z., Lewis R.E., Kontoyiannis D.P. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin. Microbiol. Rev. 2011;24:411–445. doi: 10.1128/CMR.00056-10. - DOI - PMC - PubMed
    1. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin. Microbiol. Rev. 2000;13:236–301. doi: 10.1128/CMR.13.2.236-301.2000. - DOI - PMC - PubMed
    1. Andresen D., Donaldson A., Choo L., Knox A., Klaassen M., Ursic C., Vonthethoff L., Krilis S., Konecny P. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet. 2005;365:876–878. doi: 10.1016/S0140-6736(05)71046-1. - DOI - PubMed